Professional Documents
Culture Documents
Ma Huang Ephedra Hebra
Ma Huang Ephedra Hebra
APRIL 2003
icant and persistent facial scarring, atrophy, and hy- binding to cultured human keratinocytes of antibodies specific
for SSA/Ro and SSB/La. J Immunol 1988;141:1480-8.
perpigmentation resulting from NLE. In this case,
6. McCune AB, Weston WL, Lee LA. Maternal and fetal outcome in
bleaching agents, tretinoin, and photoprotection neonatal lupus erythmatosus. Ann Intern Med 1987;106:518-23.
provided substantial cosmetic improvement. 7. Weston WL, Morelli JG, Lee LA. The clinical spectrum of
anti-Ro positive cutaneous neonatal lupus erythematosus.
REFERENCES J Am Acad Dermatol 1999;40:675-81.
1. Franco HL, Weston WL, Peebles C, Forstot SL, Phanuphak P. Au- 8. Thornton CM, Eichenfield LF, Shinall EA, Siegfried E, Rabinowitz
toantibodies directed against sicca syndrome antigens in the LG, Esterly NB, et al. Cutaneous telangiectases in neonatal lupus
neonatal lupus syndrome. J Am Acad Dermatol 1981;4:67-72. erythematosus. J Am Acad Dermatol 1995;33:19-25.
2. Dugan EM, Tunnessen WW, Honig PJ, Watson RM. U1RNP anti- 9. Crowley E, Frieden IJ. Neonatal lupus erythematosus: an unusual
body-positive neonatal lupus. Arch Dermatol 1992;128:149-4. congenital presentation with cutaneous atrophy, erosions, alope-
3. Provost TT, Watson R, Gammon WR, Radowsky M, Harley cia, and pancytopenia. Pediatr Dermatol 1998;15:38-42.
JB, Reichlin M. The neonatal lupus syndrome associated with 10. Lee LA, Weston WL. Cutaneous lupus erythematosus during
U1RNP antibodies. N Engl J Med 1987;316:113-8. the neonatal and childhood periods. Lupus 1997;6:132-8.
4. Miyagawa S, Kitamura W, Yoshioka J, Sakamoto K. 11. Chung-E T, Buyon JP. Neonatal lupus syndromes. Rheum
Placental transfer of anticytoplasmic antibodies in annular Dis Clin North Am 1997;23:31-54.
erythema of newborns. Arch Dermatol 1981;117:569-72. 12. Silverman ED, Laxer RM. Neonatal lupus erythematosus.
5. Furukawa F, Lyons MB, Lee LA, Coulter SM, Norris DA. Estradiol Rheum Dis Clin North Am 1997;23:599-618.
We describe a case of nonpigmenting solitary fixed drug eruption appearing on the right thigh of a 31-year-old
woman in Japan. The causative drug was determined by closed patch test on postlesional skin as a Chinese traditional
herbal medicine, ma huang (Ephedra Hebra), mainly containing pseudoephedrine and ephedrine. (J Am Acad Dermatol
2003;48:628-30.)
Administration. According to this report, 47% were fixed drug eruption due to pseudoephedrine. Ann Allergy
cardiovascular symptom such as hypertension, myo- Asthma Immunol 1998;80:309-10.
7. Anibarro B, Seoane FJ. Nonpigmenting fixed exanthema
cardial infarction, and stroke, and 18% were central in-duced by pseudoephedrine. Allergy 1998;53:902-3.
nervous system events such as seizures. Furthermore, 8. Krivda SJ, Benson PM. Nonpigmenting fixed drug
hepatotoxic effects have also been reported.17 As these eruption. J Am Acad Dermatol 1994;31:291-2.
medicines containing Ephedra Hebra are now popular in 9. Camisa C. Fixed drug eruption due to pseudoephedrine.
Cutis 1988;41:339-40.
the world, NPFDE or other forms of drug eruption
10. Hauken M. Fixed drug eruption and pseudoephedrine.
caused by Chinese traditional herbal medicines should be Ann Intern Med 1994;120:442.
taken into consideration in any country. 11. Valsecchi R, Cainelli T. Nonpigmenting fixed drug reaction to
piroxicam. J Am Acad Dermatol 1989;21:1300.
REFERENCES 12. Desmeules H. Nonpigmenting fixed drug eruption after
1. Abramowitz EW, Noun MH. Fixed drug eruptions. Arch anes-thesia. Anesth Analg 1990;70:216-7.
Derma-tol Syphil 1937;35:875-92. 13. Benson PM, Giblin WJ, Douglas DM. Transient,
2. Shelley WB, Shelley ED. Nonpigmenting fixed drug nonpigmenting fixed drug eruption caused by radiopaque
eruption as a distinctive reaction pattern: examples contrast media. J Am Acad Dermatol 1990;23:379-81.
caused by sensitivity to pseudoephedrine hydrochloride 14. Roetzheim RG, Herold AH, Van Durme DJ.
and tetrahydrozoline. J Am Acad Dermatol 1987;17:403-7. Nonpigmenting fixed drug eruption caused by diflunisal. J
3. Alanko K, Kanerva L, Mohell-Talolahti B, Jolanki R, Am Acad Dermatol 1991;24:1021-2.
Estlander T. Nonpigmented fixed drug eruption from 15. Garcia Ortiz JC, Terron M, Bellido J. Nonpigmenting fixed
pseudoephedrine. J Am Acad Dermatol 1996;35:647-8. exan-thema from ephedrine and pseudoephedrine.
4. Quan MB, Chow WC. Nonpigmenting fixed drug eruption Allergy 1997;52: 229-30.
after pseudoephedrine. Int J Dermatol 1996;35:367-70. 16. Haller CA, Benowitz NL. Adverse cardiovascular and central
5. Hindioglu U, Sahin S. Nonpigmenting solitary fixed drug nervous system events associated with dietary supplements
erup-tion caused by pseudoephedrine hydrochloride. J Am containing ephedra alkaloids. N Engl J Med 2000;343:1833-8.
Acad Der-matol 1998;38:499-500. 17. Stickel F, Egerer G, Seitz HK. Hepatotoxicity of
6. Vidal C, Prieto A, Perez-Carral C, Armisen M. Nonpigmenting botanicals. Pub-lic Health Nutr 2000;3:113-24.
Dermatobia hominis is the most common cause of myiasis in Central and South America, affecting mammals and
humans, causing nonhealing furuncle-like lesions. During the years 1994 to 1999, 14 Israeli travelers returning from
South America were diagnosed with D hominis myiasis. The approach consists of correct diagnosis and a proper
removal of the larvae, after which the patients heal with no complications. (J Am Acad Dermatol 2003;48:630-2.)